Search results for: 'compani diagnostics deal and alliance of 221b'

Precision Medicine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Biomarker Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Infectious Disease Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2019 to 2026

Precision Medicine in Oncology Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Global Biotech Partnering Terms and Agreements 2018 to 2023 report provides a detailed understanding and analysis of how and why companies enter biotech partnering deals.

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals

Specialty Pharmaceutical Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals. 

Oncology Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2020 to 2026

Autoimmune Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2026

Provides comprehensive understanding and unprecedented access to the animal health agreements entered into by the world's leading biopharma companies.